CGIX up +16.50% percent right now. $CGIX High is a

CGIX up +16.50% percent right now. $CGIX High is at 7.94 and the Low 6.76 with current volume of 171,103.

Recent News posted below.

CGIX Cancer Genetics Inc Recent Headline News

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 45 mins ago

UCP: 11.90 (-1.89), JRJC: 6.24 (+0.73), NAVB: 1.03 (-0.19), SANW: 3.79 (+0.71), PLPM: 1.63 (+0.26), RYN: 28.80 (-5.10), INFU: 3.00 (-0.49), LIOX: 5.46 (+0.72), DY: 27.75 (-3.12), MTZ: 25.16 (-3.47), CGIX: 6.92 (+0.92), MUX: 1.25 (-0.16), OREX: 5.11 (+1.26), URRE: 2.59 (+0.65), ACHN: 12.56 (+2.45), REN: 2.83 (-0.78), MPO: 3.34 (+0.23), AKBA: 9.38 (-1.32), TRX: 1.02 (-0.20), PLNR: 7.53 (+1.13)

Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - 2 hrs 17 mins ago

CGIX: 6.92 (+0.92)

Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - 2 hrs 42 mins ago

CGIX: 6.92 (+0.92)

Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 6.92 (+0.92)

Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST

CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 6.92 (+0.92)

Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company", an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company", an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 6.92 (+0.92)

Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company", an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 6.92 (+0.92)

Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry
GlobeNewswire - Wed Aug 27, 6:59AM CDT
-- Online database allows clinicians and patients to search for genetic and genomic tests by disease state
CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma
GlobeNewswire - Mon Aug 25, 7:30AM CDT
-- Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin's lymphoma
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. Completes Acquisition of BioServe India, a Premier Genomics and Next-Generation Sequencing Company
GlobeNewswire - Sun Aug 17, 11:00PM CDT
-- Cancer Genetics Now Positioned to Participate in High-Growth Indian Diagnostics Market, Where More Than 1 Million New Cancer Cases Are Diagnosed Each Year
CGIX: 6.92 (+0.92)

Cancer Genetics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:05AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial results for the second quarter and six months ended June 30, 2014.
CGIX: 6.92 (+0.92)

BioNano Genomics Announces The Purchase Of The Irys System By The Wellcome Trust Sanger Institute
PR Newswire - Tue Aug 12, 7:00AM CDT
BioNano Genomics announced today the purchase of an IrysTM System by the Wellcome Trust Sanger Institute, one of the world's leading genome centers, located near Cambridge, UK. The Sanger Institute made the largest single contribution to the gold standard sequence for the Human Genome Project and today is focused on the role of genetics in health and disease. The Sanger Institute purchased BioNano's Irys platform to detect structural variation and complete genomes for various projects including the Cancer Genomics Project, which seeks to develop new ways of detecting rearrangements in cancer samples, and the Parasite Genomics Team, which is sequencing the genomes of parasites that cause malaria and neglected tropical diseases prevalent in the developing world.
CGIX: 6.92 (+0.92)

Cancer Genetics to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014
GlobeNewswire - Fri Aug 08, 7:56AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time to discuss the second quarter financial results, the closing of the Gentris acquisition, the proposed FDA regulatory framework, and to answer questions.
CGIX: 6.92 (+0.92)

RedChip Issues Research Update on Cancer Genetics
GlobeNewswire - Thu Aug 07, 11:09AM CDT
RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 6.92 (+0.92)